Core Insights - AC Immune SA is focusing its investments on key assets, particularly three clinical-stage active immunotherapy programs and promising small molecule programs targeting NLRP3 and Tau [2][5] - The company plans to reduce its workforce by approximately 30% to enhance operational efficiency and extend its cash runway to the end of Q3 2027 [2][9] - CEO Dr. Andrea Pfeifer highlighted the progress in product candidates aimed at treating neurodegenerative diseases and the importance of ongoing collaborations with major pharmaceutical companies [3][4] Financial and Operational Strategy - The strategic review has led to a sharper focus on late-stage clinical development, particularly for Alzheimer's and Parkinson's diseases [9] - As of June 30, 2025, AC Immune reported cash resources of CHF 127.1 million, which will support operations until the end of Q3 2027, excluding potential milestone payments from partnerships [9] - The company maintains its guidance on clinical timelines, with interim data from ACI-7104.056 and ACI-24.060 expected in H2 2025 and H1 2026, respectively [5] Workforce and Employee Support - A consultation process with employees has been initiated in accordance with Swiss employment law, with support measures including severance packages and assistance in job placement [6] - The full implementation of workforce changes is expected by the end of 2025, with cost reductions becoming effective early in 2026 [6] Company Overview - AC Immune is a clinical-stage biopharmaceutical company specializing in precision therapeutics for neurodegenerative diseases, with validated technology platforms, SupraAntigen® and Morphomer® [7] - The company has a diversified pipeline featuring therapeutic and diagnostic programs, with significant potential for milestone payments exceeding $4.5 billion from strategic partnerships [7]

Company Overview - AC Immune has a broad and diverse pipeline of 16 programs, including 1 in Phase 3 and 5 in Phase 2, focused on neurodegenerative diseases [4] - The company has potential milestones exceeding CHF 4.3 billion through multiple global partnerships [4] - As of March 31, 2024, AC Immune has cash reserves of CHF 104.8 million, plus $100 million upfront from Takeda, funding operations into 2027 [4, 7] - The company anticipates a 2024 annual cash burn of CHF 65 million – 75 million [17] Pipeline and Milestones - AC Immune's pipeline includes clinical stage programs targeting Alzheimer's disease (AD), Parkinson's disease (PD), and other a-synucleinopathies [12] - Key milestones in H2 2024 include initial 6-month amyloid plaque data from the ABATE Phase 1b/2 trial of ACI-24.060 in AD, interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial of ACI-7104.056 in PD, and first patient in Phase 2b clinical trial (ReTain) of ACI-35.030 [21] - The company is developing TDP-43-PET tracer with Phase 1 initiation planned [21] Technology and Partnerships - AC Immune's SupraAntigen platform is designed to stimulate the patient's immune system to produce their own antibodies, offering potential advantages over passive immunotherapy [22] - The company entered into a deal with Takeda for ACI-24.060, including a $100 million upfront payment and potential payments up to approximately $2.1 billion [29] - ACI-35.030 induced anti-ePHF Ab responses in 100% of patients after the first injection [46] Financials - The company's total potential deal value exceeds CHF 4.75 billion, including upfront payments of CHF 255.2 million and milestones received of CHF 147.4 million [83]

Core Insights - AC Immune SA is set to present its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) in Vienna, Austria, from April 1 to 5, 2025, focusing on active immunotherapies for neurodegenerative diseases [1][4] Group 1: Upcoming Presentations - The company will host an industry symposium on April 2, 2025, featuring key opinion leaders discussing advances in clinical development of active immunotherapies [2] - Presentations will cover topics such as disease modification in Parkinson's disease, targeting alpha-synuclein, and precision prevention strategies for Alzheimer's disease [2][3] - The symposium will include a Q&A session and a replay will be available on AC Immune's website [2] Group 2: Research and Development Highlights - AC Immune's pipeline includes Morphomer® small molecules targeting Tau for Alzheimer's disease treatment, with a presentation scheduled for April 5, 2025 [3] - The company is developing Morphomer-antibody drug conjugates, a new class of drugs for neurodegenerative diseases [3] - Research on therapeutic small molecules targeting alpha-synuclein aggregation will also be presented [3] Group 3: Company Overview - AC Immune is a clinical-stage biopharmaceutical company focused on precision prevention for neurodegenerative diseases, leveraging its two technology platforms, SupraAntigen® and Morphomer® [6] - The company has a diversified pipeline featuring candidates in Phase 2 and Phase 3 development, with significant strategic partnerships leading to over $4.5 billion in potential milestone payments and royalties [6]